Sagility Limited
(Formerly Sagility India Limited, earlier Sagility India Private Limited)
Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur 
Road, Bommanahalli, Bengaluru – 560068, Karnataka, India
Corporate Identification Number: L72900KA2021PLC150054
Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagilityhealth.com
Date: January 28, 2026
To, 
The Manager The Manager
Listing Department Listing Department
National Stock Exchange of India Limited (NSE) BSE Limited (BSE)
Exchange Plaza, 5th Floor Phiroze Jeejeebhoy Towers
Plot No. C/1, G-Block Dalal Street
Bandra-Kurla Complex Mumbai - 400 001
Bandra (E), Mumbai - 400 051 Scrip Code:544282
Symbol: SAGILITY
Dear Sir/Ma’am, 
Sub: Submission of Investor Presentation to be made to investors on January 28, 2026, pursuant 
to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure 
Requirements) Regulations, 2015.
In continuation of our letter dated January 19, 2026, please find enclosed the presentation to be made to 
investors on the financial results of Sagility Limited for the quarter ended December 31, 2025, during 
the meeting scheduled today, i.e., Wednesday, January 28, 2026, at 7:30 p.m. (IST).
The details are also being made available on the Company’s website https://sagilityhealth.com/
This is for your information and record.
Thanking You,
For Sagility Limited
Satishkumar Sakharayapattana Seetharamaiah
Company Secretary & Compliance Officer
M. No. A16008
Encl: a/a
~ sagility'" 

Investor Deck – Q3 FY26
Jan 28, 2026

Safe Harbour
2
Certain statements in this presentation concerning Sagility’s future growth prospects may be seen 
as forward-looking statements, which involve a number of risks and uncertainties that could cause 
actual results to differ materially from such statements. Sagility does not undertake to update any 
such statements that may have been made from time to time by or on behalf of the company.

Performance Highlights
₹ 19,712 
million
Organic Y-o-Y 
growth
19.9%
13.9 % at Constant 
Currency
Y-o-Y growth
35.7%
29.1% at Constant 
Currency
₹ 5,125
million
Margin %
26.0%
Y-o-Y growth 
24.2%
₹ 3,229 
million
Margin %
16.4%
Y-o-Y growth 
23.0%
₹ 51,686 
million
Organic Y-o-Y 
growth
18.0%
13.5 % at Constant 
Currency
Y-o-Y growth
29.2%
24.2% at Constant 
Currency
₹ 13,164 
million
Margin %
25.5%
Y-o-Y growth 
25.3%
₹ 8,236 
million
Margin %
15.9%
Y-o-Y growth 
44.3%
► 19.9% Y-o-Y organic growth in Q3 FY26, driven by continued 
expansion within existing clients, and increasing contribution from 
new clients acquired in FY26
► $30.5 M (potential steady state ACV) of new business & expansion 
won in Q3 FY26
► Expansion and new SOWs from 22 existing clients in Q3 FY26
► 3 new clients onboarded in Q3 (total 12 until Q3 FY26)
► Strong performance in Broadpath coming from AEP 
► CSAT in 2025 surpassed the industry median, reflecting strong 
operational excellence, deep domain expertise, and our strategic & 
advisory engagement with clients.
Q3 FY26 summary 9M FY26 summary
Headcount
48,522
Clinicians & 
Technology heads 
4100+
► Innovator in RCM Business Process Transformation Avasant’s RadarView 2025
► Sagility is recognized among India’s Best Workplaces in Pharmaceuticals, Healthcare, and Biotech 
2025
► Earned the Ecovadis Committed Badge as a recognition to our strong performance in Sustainability
► Recognized at HIMAP (Healthcare Information Management Association of the Philippines) 2025

KPIs
4
Note: 
Adjusted EBITDA represents EBITDA adjusted for earnouts payable under acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
Adjusted PAT includes adjustments to the EBITDA and adj. for amortisation of intangible assets that got created due to carveout of healthcare business from HGS & exceptional items (represents adjustment for labour codes) 
Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis
Q3 FY26 Q2 FY26 Q3 FY25 YoY% 9M FY26 9M FY25 YoY%
Revenue from Operation (in INR Million) 19,712 16,585 14,531 35.7% 51,686 40,014 29.2%
Revenue by Vertical Split
By Payer % 90.4% 88.5% 89.3% 89.2% 89.2%
By Provider % 9.6% 11.5% 10.7% 10.8% 10.8%
Growth in revenue from operation (%) 35.7% 25.2% 15.3% 29.2% 15.3%
Adjusted EBITDA (in INR Million) 5,125 4,352 4,127 24.2% 13,164 10,508 25.3%
Adjusted EBITDA % 26.0% 26.2% 28.4% 25.5% 26.3%
Adjusted PAT (in INR Million) 3,229 3,010 2,626 23.0% 8,236 5,709 44.3%
Adjusted PAT % 16.4% 18.1% 18.1% 15.9% 14.3%
Total Number of Employees 48,522 44,185 39,595 22.5% 48,522 39,595 22.5%
Voluntary attrition rate* (%) 22.8% 26.3% 21.8% 24.7% 24.8%
.............. r---
1 
................................ l .. 
I 
I ................................. ~•---- ----~ 
i 
........... 1 
.. ::::::::::L. I -~--1 
................ ............ "i 
I 
..•..•..•..•..•..•..•..•..•..•.• l. .•. ~-

Annual KPIs
5
9M FY26 FY25 FY24 FY23
Numbers of Client group
Active 81 75 44 35
Number of new client addition (Gross) 12 38 13 7
Delivery Sites
Number of delivery sites 35 33 30 27
New site addition (Gross) 4 10 4 2
TTM Dec 25 FY25 FY24 FY23
Client groups contribution to revenues**
Top 3 Client % 60.1% 66.2% 68.3% 72.4%
Top 5 Client % 71.1% 77.9% 79.2% 80.6%
Top 10 Client % 84.6% 90.5% 91.4% 90.7%
Number of Million-dollar client groups
Number of clients contributing more than US$20 million 8 7 5 4 
Number of clients contributing to US$5 - US$20 million 7 6 7 7 
Number of clients contributing to US$1 - US$5 million 22 12 12 12 
Number of clients contributing less than US$1 million 44 50 20 12 
• Client groups comprise client entities together with their affiliates.
• **Client group represent top client based on last twelve months revenue for the respective period 

6
Recent Market Updates
► STARS focus shifting toward clinical safety and 
patient experience and away from low-value 
admin measures. 
► This is likely to accelerate demand for clinical 
and care coordination, member experience, and 
behavioral health follow-up at scale.
CMS proposed changes in 2027 
in MA & Part D (2027)
► OEP 2026 provisional results indicate a decline in 
ACA selections by 3.4% largely due to expiration of 
Premium tax credits leading to increase in 
premiums.
► Health plans with heavy ACA exposure would be 
affected; some large insurers have not participated
► For service providers, outsourcing demand will shift 
toward post-enrollment support to protect 
membership and revenue; Sagility has very little 
exposure to ACA plans 
ACA subsidy expiration 
HEDIS Measurement Year 2026 PBM Market evolution
► New HEDIS measures to increase focus on 
care coordination; push towards digital and 
FHIR-aligned reporting
► These changes are likely to increase demand 
for HEDIS abstraction and outreach support
► PBM market faces higher scrutiny on price 
transparency by both FTC and State regulatory affairs . 
► Employers and Insurers demand higher accountability 
for clinical outcomes from PBMs. 
► High-cost drugs such as GLP-1 demand stronger 
coverage policies and cost sharing by insured 
members

Medicare AEP 2026 & ACA Marketplace OEP 2026
7
Industry View
► National carriers reporting Medicare AEP 
largely in line with expectations. 
► Payers shift focus towards Margin Repair 
over Membership Growth -better risk mix 
and higher-STAR cohorts, rather than higher 
enrollment.
► 2026 is expected to be a consolidation phase 
with reduced participation in lowmargin/high-utilization populations.
► CMS overall data on AEP 2026 would be 
available Mid-Feb
Medicare
► To date, there was 29% decline in new 
consumers and 3.4% decline in total 
enrollment in 2026 vs 2025 
► Expiration of ACA premium tax credits 
resulting in higher net premiums is 
leading to the churn
ACA
Specific to Sagility’s large 
payer relationships, AEP 
outcomes were broadly 
ahead of expectations
As mentioned earlier, 
Sagility has very low 
exposure to the ACA 
segment
1. Higher administrative throughput 
(engagement service volumes, PA, claims, 
clinical workflows)
2. Cost management pressure
3. Heightened emphasis on Stars recovery, 
clinical quality, and automation.
Industry-wide, plans continue to shift 
budgets toward:
1. Digital/AI-led operating models
2. Outsourcing to improve margins while 
retaining plan benefits.
Implications

Sagility Thought Leadership:
What’s New &What’s Nextfor 2026
8
Dynamic Content White Paper & Case Studies
Whitepaper
Case Studies
AI, RPA Improves
Dental Appeals, Boosting
Efficiency by 30%,
Accuracy by 50%
Scaling Healthcare Operations 
with Geographical Flexibility 
& Process Maturity
GenAI Nurse Assist to 
Achieve Efficiencies, Faster 
Care
Reducing cost by 30% 
with Optimized Provider 
Data
Sagility Consulting A person holding a tablet
AI-generated content may be incorrect.
A person holding a tablet
AI-generated content may be incorrect.
Blog Posts
Unlocking Member Value with 
AI-Empowered Experiences
GTM with Sagility Synchrony
People and Data: Key to Member 
Experience Transformation
GenAI Client Use cases: 32 client use cases deployed across 10 clients
~ sagility· 
Sagility Synchron~ A Medicare Advantage 
Lifecycle Solution. 
M«ficafe AdVantage plans are being asked 1odo fflOfe fOf 
increasingly comP'911.. high-need membef populations. This is COffllf19 
at• time when costs a,e rising, regt,jato,y scrutiny Is Intensifying. and 
«rOl'•PfOM ..-volmenl and billng operations are putting MA Star 
Ratlngsatrkk. 
As 2027 bid and benefll: decbions app,oac:h, many p,Yns remain 
constralMdbyfr~ntedpolnt solutions NtwttrenwwdfflgMd 
to scale, integrate, Of perlorm in today's hNlthcWe ecosystem. 
Sag1hty Synchrony• .. in'llnatff si!Md open1k>ns by unifying plan 
filing, launch, sales, bfok« management, enrolment, biD1ng, and 
u.,.to-market, 
reconciliation 
~ 
on 
Improving 
an integrated, 
data Integrity, 
compbnl. 
reduchg 
W0f1d'low 
auclk 
- ~ 
rtsk,. and 
fnction in the membef ••peMn(:a. 
* ~ 
-~ .. 
"""'"""""' modelthMICllles 
wlthmambenhlp 
~ sagility· -~ .. fi!lconvey 
~ sagility 
Activating 
Outsourced 
Healthcare 
Operations 
A step-by-step playbook 
for speed, scale, and stability 
====-I - ro 
-------------
------------
--------
Iii 
~I 

Financial Highlights

Financial Highlights
10
Q3 FY26 9M FY26
₹ 19,712 
million
Organic Y-o-Y 
growth
19.9%
13.9 % at Constant 
Currency
Y-o-Y growth
35.7%
29.1 % at Constant 
Currency
₹ 5,125
million
Margin %
26.0%
Y-o-Y 
growth %
24.2%
₹ 3,229 
million
Margin %
16.4%
Y-o-Y 
growth %
23.0%
₹ 51,686
million
Organic Y-o-Y 
growth
18.0%
13.5 % at Constant 
Currency
Y-o-Y growth
29.2%
24.2 % at Constant 
Currency
₹ 13,164
million
Margin %
25.5%
Y-o-Y 
growth %
25.3%
₹ 8,236 
million
Margin %
15.9%
Y-o-Y 
growth %
44.3%
₹ 6,708 
million
Conversion %
49.7%
DSO
86 days
₹ 1,117
million
Conversion %
21.7%
DSO
86 days
Higher Revenues in Q3 leading to increase in DSO to 86 days ( AR 51 Days, Unbilled 35 days) & Drop in cash conversion 

z
12,602 12,832 12,233 
13,250 
14,531 
23.0% 24.5% 23.8% 26.1% 28.4%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
 4,000
 6,000
 8,000
 10,000
 12,000
 14,000
 16,000
 18,000
 20,000
 22,000
Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25
Revenue INR M Adjusted EBITDA %
Quarterly Seasonality
36.6 35.0 35.9 38.4
39.6 39.4 39.9
Headcount 
(‘000) 44.2
39.6
48.5
11
Sep 23 to 
Dec 24
Headcount 
(‘000)
BroadPath
Revenue ($M) $150.8 $154.4 $146.6 $157.9 $171.9
Revenue ($M) $171.9 $181.8 $180.4 $189.4 $222.0
Higher growth in Q3 driven by strong AEP for Broadpath & Sagility Organic business
14,531 
15,685 15,389 
16,585 
19,712 
28.4% 26.6% 24.0% 26.2% 26.0%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
 4,000
 6,000
 8,000
 10,000
 12,000
 14,000
 16,000
 18,000
 20,000
 22,000
Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26
Revenue INR M Adjusted EBITDA %
Dec 24 to 
Dec 25
·----------------1 
' ' ' ' ' ' ' ' ·----------------, : ' ' ' ' - - - - - - - - - - - - - - - - _1 ' 
·----------------1 
' ' ' ' ' ' •-- ' ------- ___ -:_-:_I ' 
' ' ' ' ~ - - - - - - - - - - - - - - - _I 
·----------------, ' I 
' I ________________ ' 1 
,----------------1 
: --------------- ! 
. ---------------- ' ' ' I--------------- ' 
0 
' L-- ------------ -
' ; ' ' ' - - - - - - - - - - - - - - - - _1 ' ,----------------1 
L ____ ------- ____ _! 
- ·----------------1 
: ' 
' ' ' - _________ ,:,:,:_-,:-1 
' ' : ' 
' ----------------
,-------------------------------~ ·----------------, : ' ' ' ' - - - - - - - - - - - - - - - - _1 ' ·----------------, : ' ' ' ' - - - - - - - - - - - - - - - - _1 ' 
·----------------1 
: ' 
' I ________________ 1 
I - -----1 
' ' ' ' ~ - -- --- ------- -- _[ 
•----------------r 
' ' ' ' ' I ________________ ' 1 
•----------------r 
: : 
' I ________________ ' 1 
I -------------1 
' ' ' ' L--------------- ' ' I ·----------------1 
' ' ' ' I ________________ I 
I 
I 
I 
I 
I 
I ~-------------------------------' 

Long Term Financial performance snapshot
Revenue 
(INR Million) 
FY25 YoY% TTM Dec YoY%
17.2% 27.5%
Adjusted EBITDA * 
(INR Million)
FY25 YoY% TTM Dec YoY%
28.4% 27.0%
Adjusted PAT
(INR Million)
FY25 YoY% TTM Dec YoY%
37.5% 44.5%
Revenue ($M) 
FY25 YoY% TTM Dec YoY%
14.9% 22.6%
Adjusted EBITDA* 
($M)
FY25 YoY% TTM Dec YoY%
25.9% 22.2%
Adjusted PAT
($M)
FY25 YoY% TTM Dec YoY%
34.8% 39.0%
12
*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI, & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
Consistent Revenue & EBITDA growth. Reduction in interest and amortization expense driving higher PAT growth 
₹47,536
₹55,699 ₹52,846
₹67,371
FY24 FY25 TTM Dec 24 TTM Dec 25
₹11,436
₹14,685 ₹13,651
₹17,341
FY24 FY25 TTM Dec 24 TTM Dec 25
₹5,896
₹8,107 ₹7,360
₹10,634
FY24 FY25 TTM Dec 24 TTM Dec 25
$572.9
$658.3 $630.9
$773.6
FY24 FY25 TTM Dec 24 TTM Dec 25
$137.8
$173.6 $162.9
$199.2
FY24 FY25 TTM Dec 24 TTM Dec 25
$71.1
$95.8 $87.9
$122.1
FY24 FY25 TTM Dec 24 TTM Dec 25
• • 
t t t t t t 
t t t t t t 
I 
• • 

Other Financial Indicators
Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares
Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities)
Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent including investment in Mutual Fund and Deposits . Borrowing doesn’t include accrued interest
13
Steady Increase in Adjusted EPS. Adjusted ROCE consistent at 50%. Lower cash conversion in YTD Dec’25 due to higher DSO, Non cash gains & taxes 
1.38 
1.76 
2.27 
FY24 FY25 TTM Dec 25
Adjusted EPS (in INR)
47.0%
54.9% 53.5%
FY24 FY25 TTM Dec 25
Adjusted ROCE %
₹21,678
₹10,433
₹6,426
1.9x
0.71x
0.37x -
 0.50
 1.00
 1.50
 2.00
 2.50
₹0
₹5,000
₹10,000
₹15,000
₹20,000
₹25,000
FY24 FY25 TTM Dec 25
Net Debt
Net Debt (in INR Million) Net Debt to Adjusted EBITDA
87.2% 89.7%
49.7%
70.8%
80.5%
39.7%
FY24 FY25 9M FY 26
Cash Conversion (%)
■ OCF % FCF %
-

Q3 FY26 Consolidated Profit and Loss
14
*Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), 
^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately.
** Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
Amt in INR M
Particulars Q3 FY26 Q2 FY26 Q3 FY25 YoY% QoQ% 9M FY26 9M FY25 YoY%
Revenue from Operation 19,712 16,585 14,531 35.7% 18.9% 51,686 40,014 29.2%
Employee benefits expense 12,211 10,070 8,415 31,926 23,854
Other expenses^ 2,376 2,163 1,988 6,596 5,652
Adjusted EBITDA** 5,125 4,352 4,127 24.2% 17.8% 13,164 10,508 25.3%
Adjusted EBITDA % 26.0% 26.2% 28.4% 25.5% 26.3%
Adjustments:
M&A Earnouts 42 127 120 324 364
SAR (stock appreciation right) - NonCash -61 73 85 83 1,030
Other Income (excl. Forex gain)^^ 84 65 99 199 287
Forex Gain / (Loss) -33 516 341 533 309
Reported EBITDA 5,195 4,733 4,362 19.1% 9.8% 13,488 9,710 38.9%
Finance costs 247 250 302 771 973
Depreciation and amortisation expenses 1,235 1,215 1,162 3,632 3,525
Profit before Exceptional Items 3,713 3,268 2,898 28.1% 13.6% 9,085 5,212 74.3%
Statutory impact of new labour code in India 328 328
Profit Before Tax 3,385 3,268 2,898 16.8% 3.6% 8,757 5,212 68.0%
Tax Expenses 709 760 729 2,087 1,647
Reported Profit After Tax 2,677 2,508 2,169 23.4% 6.7% 6,670 3,565 87.1%
EPS 0.57 0.53 0.46 23.9% 6.9% 1.42 0.78 82.7%
Adjusted PAT 3,229 3,010 2,626 23.0% 7.3% 8,236 5,709 44.3%
Adjusted PAT % 16.4% 18.1% 18.1% 15.9% 14.3%
Adjusted EPS (Rs) 0.69 0.64 0.56 23.0% 7.3% 1.76 1.24 41.7%
► Prescribes uniform definition 
of wages based on which 
employee benefits like 
gratuity, leave encashment & 
statutory bonus are 
computed. 
► Past service costs of INR 
294.7M towards Gratuity and 
INR 33.5M towards 
Compensated absence 
reported as exceptional 
items in Q3.
► Ongoing impact on overall 
Margins is likely to be 0.2% of 
Revenues.
New Labour Code in India 
effective 21Nov 2025: 
................ .... ............. ~ 
··········r· J .......... L 
··························}·· 
··········r·· 
I 
'· 
... ::::::::::1 ..... . . . : : 
E 

Adjustments on EBITDA and PAT
Adj EBITDA Bridge: Q3 FY26
Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax
Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible)
Adj C - Amortization of intangible assets (net of tax) that got created due to carveout of healthcare business from HGS
Adj D- Exceptional items for Q3 FY26 represents adjustment for labour codes (net of deferred tax) on account of increase in gratuity liability arising out of past service cost and increase in leave liability
Adj PAT Bridge: Q3 FY26
15
Adj EBITDA Bridge: 9M FY26
Adj PAT Bridge: 9M FY26
Reported 
EBITDA Adj A Adj B Other income/ 
FX gain Adjusted EBITDA Reported 
EBITDA Adj A Adj B Other income/ 
FX gain Adjusted EBITDA
₹5,195 ₹42
-₹61 -₹51
₹5,125
Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA
₹13,488 ₹324 ₹83
-₹732
₹13,164
Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA
₹6,670 ₹236 ₹83
₹1,001 ₹246 ₹8,236
Reported PAT Adj A Adj B Adj C Adj D Adjusted PAT
₹0
₹1,000
₹2,000
₹3,000
₹4,000
₹5,000
₹6,000
₹7,000
₹8,000
₹9,000
₹2,677 ₹30
-₹61
₹338
₹246 ₹3,229
Reported PAT Adj A Adj B Adj C Adj D Adjusted PAT
₹0
₹500
₹1,000
₹1,500
₹2,000
₹2,500
₹3,000
₹3,500
Amt in INR M Amt in INR M
- -

Go Forward Positions
• Intangibles Amortisation (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS
• Intangibles Amortisation (B) - Amortisation for intangible assets acquired in relation to acquisitions (DCI, Birch and BroadPath) – Ends by FY33 
16
Particulars FY25 FY26 FY27 FY28 FY29 FY30
Closing Debt position 8,020 5,670
Debt Repayment 2,490 2,350 5,670
Interest Payment 751 535 285
Share based Payment awards 1,134 117 117 62 30
Earnouts Cost - DCI / Birch/ BroadPath 571 420 6
Intangibles Amortisation (A) 1,400 1,451 1,487 1,487 1,487 1,487
Intangibles Amortisation (B) 188 391 388 374 297 252
Amt in INR M
Debt to be fully repaid by FY27.

Balance Sheet – 31st December 25
17
Particulars Dec 25 Mar 25
Property, plant and equipment 4,199 3,699
Capital-work-in-progress 0 0
Right-of-use assets 4,979 5,521
Goodwill 62,108 60,390
Other intangible assets 19,886 20,362
Trade receivables and Unbilled 16,560 12,668
Cash and cash equivalents 5,789 3,438
Deferred tax assets (net) 1,474 1,337
Other Assets 3,511 3,091
Total Assets 118,507 110,507
Equity 91,899 83,361
Borrowings 6,904 8,170
Lease liabilities 5,441 5,850
Trade payables 2,038 2,136
Deferred tax liabilities (net) 3,941 4,279
Other Liabilities 8,284 6,712
Total Liabilities 118,507 110,507
Amt in INR M

Cash Flow – 9M FY26
18
Particulars 9M FY26 FY25
Profit before tax for the period/ year 8,713 7,602
Adjustment for Non-Operating and Non-Cash items 3,963 6,982
Adjustment for working capital (2,663) (710)
Income taxes paid (net of refunds) (3,310) (1,734)
Net cash flows generated from operating activities (A) - OCF 6,703 12,141
Addition to Fixed Assets (1,344) (1,244)
Free Cash flow (FCF) 5,359 10,896
Cash paid for M&A 0 (4,825)
Pending Purchase consideration paid for healthcare business carveout 0 (3,756)
Investment in Mutual fund and Fixed Deposit (4,030) 0
Others 149 184
Net cash flows (used in) investing activities (B) (5,225) (9,642)
Capital infused by promoter 0 3,708
Share Issue expense (paid)/ reimbursed 0 72
Dividend paid (234) 0
Repayment of Promoter borrowings (include Interest) (1,696) (4,567)
Repayment of lease liabilities (include Interest) (1,370) (1,774)
Net cash flows (used in) financing activities (C) (3,300) (2,561)
Net increase/ (decrease) in cash and cash equivalents (A+B+C) (1,822) (62)
Cash and cash equivalents at the beginning of the year/period 3,438 3,441
Effect of movement in exchange rates on cash and cash equivalents 82 58
Cash and cash equivalents at the end of the year/ period 1,698 3,438
Net cash flows generated from operating activities % (OCF on Reported EBITDA) 49.7% 89.7%
Free Cash flow % (FCF on Reported EBITDA) 39.7% 80.5%
Amt in INR M

Thank You